First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
EClinicalMedicine
PUBLICATIONS
TVB-2640 with Bevacizumab in Relapsed High-grade Astrocytoma
European Society for Medical Oncology (ESMO) Congress
The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH
EASL International Liver Congress
FASN inhibition as a potential treatment for therapy of endocrine resistant breast cancer
San Antonio Breast Cancer Symposium
